The Effect of Administration of Small Doses of Thyroxine on Glucose and Lipid Metabolism, in Type 2 Diabetes Mellitus.
Primary Purpose
Diabetes Mellitus
Status
Completed
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
thyroxine
Placebo
A meal (730kcal, 50%carbohydrate, of which 38% was starch, 40% fat, and 10% protein)
Sponsored by

About this trial
This is an interventional treatment trial for Diabetes Mellitus focused on measuring Diabetes mellitus, thyroxine
Eligibility Criteria
Inclusion Criteria:
- Healthy or treatment naive type 2 diabetes euthyroid subjects, with a micronodular texture of the thyroid gland.
- Recreationally active
- With stable body weight and diet during the last two months.
Exclusion Criteria:
- Any systemic disease(besides glucose abnormalities)
- Any medication therapy
- Diabetic complications
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm Type
Active Comparator
Active Comparator
Placebo Comparator
Arm Label
thyroxine in eythyroid diabetics
thyroxine in euthyroid healthy humans
placebo in euthyroid diabetics
Arm Description
50 μg of thyroxine once daily, for 2 months.
50 μg of thyroxine once daily, for 2 months.
50 μg of placebo once daily, for 2 months.
Outcomes
Primary Outcome Measures
area under the glucose uptake versus time curve-AUC
Muscle glucose uptake following meal ingestion
Secondary Outcome Measures
Plasma glucose levels following meal ingestion
area under the plasma concentration versus time curve-AUC
Plasma insulin levels following meal ingestion
area under the plasma concentration versus time curve-AUC
Plasma triglyceride levels following meal ingestion
area under the plasma concentration versus time curve-AUC
Plasma total cholesterol levels following meal ingestion
area under the plasma concentration versus time curve-AUC
Plasma LDL-cholesterol levels following meal ingestion
area under the plasma concentration versus time curve-AUC
Plasma HDL-cholesterol levels following meal ingestion
area under the plasma concentration versus time curve-AUC
Plasma Apo-A levels following meal ingestion
area under the plasma concentration versus time curve-AUC
Plasma Apo-B levels following meal ingestion
area under the plasma concentration versus time curve-AUC
Plasma Lp(α) levels following meal ingestion
area under the plasma concentration versus time curve-AUC
Plasma NEFA levels following meal ingestion
area under the plasma concentration versus time curve-AUC
Plasma glycerol levels following meal ingestion
area under the plasma concentration versus time curve-AUC
Muscle blood flow following meal ingestion
area under the plasma concentration versus time curve-AUC
Plasma thyroid hormones
measure of plasma concentration
glucose uptake by peripheral monocytes by the usage of the fluorescent analogue 6-NBDG
area under the curve of 6-NBDG uptake by monocytes under insulin stimulation
% GLUT4 increment from baseline (0mU/l) to maximal concentration (200mU/l) of insulin.
Number of participants with adverse events
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT02509858
Brief Title
The Effect of Administration of Small Doses of Thyroxine on Glucose and Lipid Metabolism, in Type 2 Diabetes Mellitus.
Official Title
The Effect of Administration of Small Doses of Thyroxine on Glucose and Lipid Metabolism, at All Stages of Type 2 Diabetes Mellitus.
Study Type
Interventional
2. Study Status
Record Verification Date
July 2015
Overall Recruitment Status
Completed
Study Start Date
February 2009 (undefined)
Primary Completion Date
February 2014 (Actual)
Study Completion Date
July 2015 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Attikon Hospital
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
We investigated the effect of the administration of small doses of thyroxine to healthy humans and patients with type 2 diabetes on postprandial forearm muscle glucose uptake, insulin sensitivity indices, lipid metabolism, in vitro glucose uptake and GLUT4 recruitment in the plasma membrane of monocytes.
Detailed Description
The present open-labeled, randomized and placebo-controlled study was undertaken in euthyroid type 2 diabetic patients and healthy humans, to examine the effect of administration of small doses of thyroxine within the euthyroid range, on muscle glucose disposal, postprandial insulin sensitivity, lipid metabolism, in vitro glucose uptake and GLUT4 recruitment in the plasma membrane of monocytes.This was investigated with the arteriovenous-difference technique after the consumption of a mixed meal and the in vitro study of a glucose analogue(6-NBDG) uptake by the peripheral monocytes.
Subjects and Methods: Eleven euthyroid, treatment naive, type-2 diabetic patients with a micronodular texture of the thyroid gland and eleven healthy euthyroid subjects, were studied before and after administration of 50 μg of thyroxine once daily for 2 months. In parallel, a placebo group was also studied. Eleven euthyroid treatment-naïve subjects with type 2 diabetes and a micronodular texture of the thyroid gland, matched for age, sex, BMI, and basal thyroid function, were studied before and after administration of a placebo, once daily for 2 months.
Experimental protocol: All subjects were admitted to the hospital at 0700 h after an overnight fast and had the radial artery (A) and a forearm deep vein (V) catheterized. A meal (730kcal, 50%carbohydrate, of which 38% was starch, 40% fat, and 10% protein) was given at least 1 h after catheter insertion and was consumed within 20 min. Blood samples were drawn from both sites before the meal (at -30 and 0 min) and at 30- to 60-min intervals for 300 min thereafter for measurements of thyroid hormones,glucose, total cholesterol, LDL Cholesterol, HDL Cholesterol, triglycerides, Apolipoprotein A1, Apolipoprotein BII and Lp(a).Forearm blood flow was measured with strain-gauge plethysmography. After the first meal tolerance test, treatment with 50μg of thyroxine or placebo, once daily, was initiated for a 2-month period. Then a second identical test was repeated. Special care was taken in order to avoid the induction of subclinical hyperthyroidism, that is suppression of TSH below 0.27 μU/ml, as it has recently been shown that the latter is also an insulin-resistant condition.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Diabetes Mellitus
Keywords
Diabetes mellitus, thyroxine
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Crossover Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
33 (Actual)
8. Arms, Groups, and Interventions
Arm Title
thyroxine in eythyroid diabetics
Arm Type
Active Comparator
Arm Description
50 μg of thyroxine once daily, for 2 months.
Arm Title
thyroxine in euthyroid healthy humans
Arm Type
Active Comparator
Arm Description
50 μg of thyroxine once daily, for 2 months.
Arm Title
placebo in euthyroid diabetics
Arm Type
Placebo Comparator
Arm Description
50 μg of placebo once daily, for 2 months.
Intervention Type
Drug
Intervention Name(s)
thyroxine
Other Intervention Name(s)
T4
Intervention Description
treatment with 50μg of thyroxine once daily for two months.
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
treatment with 50μg of placebo, once daily, for two months.
Intervention Type
Other
Intervention Name(s)
A meal (730kcal, 50%carbohydrate, of which 38% was starch, 40% fat, and 10% protein)
Primary Outcome Measure Information:
Title
area under the glucose uptake versus time curve-AUC
Description
Muscle glucose uptake following meal ingestion
Time Frame
Time Frame: 0, 30, 60, 90, 120, 180, 240, 300 min postmeal
Secondary Outcome Measure Information:
Title
Plasma glucose levels following meal ingestion
Description
area under the plasma concentration versus time curve-AUC
Time Frame
0, 30, 60, 90, 120, 180, 240, 300 min postmeal
Title
Plasma insulin levels following meal ingestion
Description
area under the plasma concentration versus time curve-AUC
Time Frame
0, 30, 60, 90, 120, 180, 240, 300 min postmeal
Title
Plasma triglyceride levels following meal ingestion
Description
area under the plasma concentration versus time curve-AUC
Time Frame
0, 30, 60, 90, 120, 180, 240, 300 min postmeal
Title
Plasma total cholesterol levels following meal ingestion
Description
area under the plasma concentration versus time curve-AUC
Time Frame
0, 30, 60, 90, 120, 180, 240, 300 min postmeal
Title
Plasma LDL-cholesterol levels following meal ingestion
Description
area under the plasma concentration versus time curve-AUC
Time Frame
0, 30, 60, 90, 120, 180, 240, 300 min postmeal
Title
Plasma HDL-cholesterol levels following meal ingestion
Description
area under the plasma concentration versus time curve-AUC
Time Frame
0, 30, 60, 90, 120, 180, 240, 300 min postmeal
Title
Plasma Apo-A levels following meal ingestion
Description
area under the plasma concentration versus time curve-AUC
Time Frame
0, 30, 60, 90, 120, 180, 240, 300 min postmeal
Title
Plasma Apo-B levels following meal ingestion
Description
area under the plasma concentration versus time curve-AUC
Time Frame
0, 30, 60, 90, 120, 180, 240, 300 min postmeal
Title
Plasma Lp(α) levels following meal ingestion
Description
area under the plasma concentration versus time curve-AUC
Time Frame
0, 30, 60, 90, 120, 180, 240, 300 min postmeal
Title
Plasma NEFA levels following meal ingestion
Description
area under the plasma concentration versus time curve-AUC
Time Frame
0, 30, 60, 90, 120, 180, 240, 300 min postmeal
Title
Plasma glycerol levels following meal ingestion
Description
area under the plasma concentration versus time curve-AUC
Time Frame
0, 30, 60, 90, 120, 180, 240, 300 min postmeal
Title
Muscle blood flow following meal ingestion
Description
area under the plasma concentration versus time curve-AUC
Time Frame
0, 30, 60, 90, 120, 180, 240, 300 min postmeal
Title
Plasma thyroid hormones
Description
measure of plasma concentration
Time Frame
baseline
Title
glucose uptake by peripheral monocytes by the usage of the fluorescent analogue 6-NBDG
Description
area under the curve of 6-NBDG uptake by monocytes under insulin stimulation
Time Frame
baseline to 600 sec
Title
% GLUT4 increment from baseline (0mU/l) to maximal concentration (200mU/l) of insulin.
Time Frame
baseline
Title
Number of participants with adverse events
Time Frame
300 min postmeal
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
Healthy or treatment naive type 2 diabetes euthyroid subjects, with a micronodular texture of the thyroid gland.
Recreationally active
With stable body weight and diet during the last two months.
Exclusion Criteria:
Any systemic disease(besides glucose abnormalities)
Any medication therapy
Diabetic complications
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
GEORGE DIMITRIADIS, MD, Phd
Organizational Affiliation
2nd Department of Internal Medicine, Research Institute and Diabetes Center, Athens University Medical School, Attikon Hospital
Official's Role
Study Director
12. IPD Sharing Statement
Learn more about this trial
The Effect of Administration of Small Doses of Thyroxine on Glucose and Lipid Metabolism, in Type 2 Diabetes Mellitus.
We'll reach out to this number within 24 hrs